根据美国证券交易委员会（SEC）最新披露的文件，生物制药公司Oric Pharmaceuticals Inc.（ORIC）宣布已启动一项股权发行计划。该公司将授权通过承销商Jefferies，在未来适时向市场不定期发售普通股股票，总筹资规模最高可达2亿美元。
此类"暂搁发行"安排为上市公司提供了灵活的融资渠道，使其能够根据市场条件和资金需求分批发行股票。此次融资计划将助力Oric Pharmaceuticals推进其肿瘤靶向治疗药物的研发管线。通过Jefferies作为销售代理，公司可更高效地把握市场窗口期优化融资结构。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.